Workflow
【私募调研记录】星石投资调研潮宏基、丸美生物等3只个股(附名单)

Group 1: Chao Hong Ji - The company has launched high-weight series products such as Zhenjin Zhenzuan and Fanhua to enhance customer price and will continue to focus on customer needs [1] - The online subsidiary's net profit increased by 70.64% year-on-year, promoting online and offline integration [1] - As of June, the number of stores reached 1,540, with a net increase of 72 stores, including international expansions in Kuala Lumpur, Thailand, and Cambodia [1] Group 2: Marubi Biological - The company is expanding its audience on Douyin through targeted content, leading to an increase in its traffic pool [2] - The strategic investments made in Q2 are expected to convert in Q4, with the brand "Lianhuo" entering a normal growth phase [2] - The three core product series account for over 70% of sales, indicating potential for further growth [2] Group 3: Meirui New Materials - The company has made progress in the functional chemical raw materials sector, with its subsidiary's polyurethane industrial park's first phase now in trial production [3] - Plans to increase capital in the Henan subsidiary aim to enhance financial strength and alleviate liquidity pressure [3] - Two fundraising projects are expected to commence by the end of 2024 and reach operational status by June 2026 [3]